This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk07: Good day and thank you for standing by. Welcome to the Sertara Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, David Dikler, Head of Investor Relations. Go ahead.
spk03: Good afternoon, everyone. Thank you all for participating in today's conference call. On the conference at Sertara, we have William Furey, Chief Executive Officer, John Gallagher, Chief Financial Officer. Earlier today, Sertara released financial results for the quarter ended June 30th, 2024. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements, and actual results may differ materially from those expressed or implied in the forward-looking statements. Please refer to slide two in the accompanying materials for additional information, which you can find on the company's investor relations website. In their remarks or responses to questions, management may mention some non-GAAP financial measures. Reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures are available on the recent earnings press release available on the company's website. Please refer to the reconciliation tables in the accompanying materials for additional information. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, August 6th, 2024. Sertara disclaims any obligation except is required by law to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. And with that, I'll turn the call over to William.
spk05: Thank you, David, and good afternoon, everyone. Thank you for joining Sertara's second quarter earnings call. John and I will begin with prepared remarks, and then we will take your questions. Sertara's second quarter performance reflects continued strength in software amid a more challenging environment in services. We have found that the pace of recovery in the market demand has been relatively mixed. There are positive signs among some biotechs, especially those in the clinical stage. But we see continued caution in the spending patterns of some tier one clients. This has affected our business segments in different ways. Our software business is growing with new products, new seats, and new clients as customers see the potential for our products to reduce costs and improve development outcomes. However, our services business is more dependent upon the overall progress of projects in the global development pipeline, where there has been reduced spending across the industry and which has impacted our near term commercial opportunities. That said, our conversations with customers indicate high interest in biostimulation over the long term and specifically in Sertara's software and services. Second quarter total revenue grew 3% to $93.3 million, which was slightly below our internal expectations. Underlying this was 13% growth in our software segment and negative 3% growth in our services. During the quarter, Sertara made efforts to optimize the allocation of resources across the business, including cost reduction actions to better position ourselves for the balance of 2024 and beyond. As we look to the future, we were encouraged to see our total bookings in the second quarter were $98.9 million, which grew 15% year over year. Throughout the quarter, the pace of commercial activity in our services business progressed towards the lower end of our expectations with tier three customers outperforming and tier one customers underperforming. We have not yet seen an inflection point at the market level in services demand, but we have seen some green shoots in the tier three customer base that are encouraged by that customer group heading into the second half of the year. We believe that our tier one customers have continued to evaluate spending priorities and pipeline development initiatives throughout the first half of the year. This has resulted in slower spending and elongated decision making, impacting our services businesses. We are encouraged by our 14% growth in services bookings for the second quarter. As we continue our continuous strength in software, re-emerging strength in biotech customers, and the normal seasonality of our business, we've continued to have confidence in our full year outlook, which we are reiterating today. The environment we have seen year to date falls within the range of outcomes we anticipated when we initiated 2024 guidance earlier this year. As we assess the remainder of the year, we believe disciplined commercial strategy, new product releases, and a stable end market keeps the revenue guidance range achievable, with the upper end of the guidance range possible with an improving end market outlook. But we are tracking to the lower half of the guidance range, of the revenue guidance range, given what we've seen during Q2 with our tier one services customers. We will continue to focus on commercial execution as we progress through the second half of the year. Next, let's touch on some recent highlights at Sertara. In the rapidly changing biopharma landscape, we're engaging with key players across the sector. During our inaugural client summit called Certainty, we brought together biosimulation experts to discuss our offerings in an interactive environment. Over 250 clients joined various tracks tailored to specific applications, networking, and engaging with the Sertara team. This May event included hands-on workshops for SimSip, Phoenix, and Pinnacle 21, plus a preview of the co-author AI regulatory writing software. The summit proved to be an excellent platform for solidifying customer relationships and promoting model-informed drug development. We have also continued to focus on investments that support the long-term adoption of biosimulation. Last month, we announced an agreement to inquire ChemAxon, a leading provider of cheminformatics software used in the discovery phase of drug development. This acquisition is expected to close in the fourth quarter subject to customary closing conditions. Used by 18 of the top 20 pharma companies, ChemAxon's tools span the design, make, and production test and analyze framework, which is used to make lead optimization and pipeline development prioritization decisions. By integrating these tools with Sertara's biosimulation products and artificial intelligence technology, we can enhance the use of model-informed drug development in the discovery and lead optimization phases. ChemAxon is expected to generate 2024 software revenues of over $20 million, with a team of over 200 employees, including more than 75 software developers. Their 2024 adjusted EBITDA margin is below Sertara's corporate average, but we have a roadmap to achieve margins approaching Sertara's corporate average adjusted EBITDA margin by the end of 2025. In the second quarter, we continue to make progress in developing new software products and product features and integrating AI across our portfolio. In early June, we released the 23rd version of SimSip, which included new features, such as advanced biomarker modeling to predict drug-drug interaction risks and expanded biopharmaceutical capabilities. Additionally, the new version of SimSip aligns with recent FDA guidelines, covering pH-dependent drug-drug interactions and therapeutic proteins that should help ensure smoother regulatory processes. We also announced the highly anticipated full commercial launch of our co-author regulatory writing software at DIA 2024. Co-author leverages generative AI to accelerate the drafting of regulatory submissions, and has demonstrated improved efficiency to first draft by greater than 30%. Co-author is another example of how Sertara is using AI technology acquired in the BiASA transaction to develop impactful products that can ultimately drive further market penetration. Early customer feedback has been very positive, and we expect the product will generate notable commercial interest as the year progresses. Wrapping up, we are working diligently to improve growth and profitability of the businesses in the second half of the year. There have been several exciting developments related to our software products this year, and we announced a strategic acquisition that will help accelerate industry adoption of model-informed drug development, particularly in the discovery phase, with strong synergistic growth opportunities. We continue to attract new customers and attract and add new products and features that impact drug development timelines and efficiencies. As I look forward to the rest of the year and beyond, I am confident in the investments we are making in our business, and that they will translate to long-term growth. With that, I will now hand things over to John to discuss our financial results in more detail.
spk10: Thank you, William. Hello, everyone. Total revenue for the three months ended June 30th, 2024 was $93.3 million, representing -over-year growth of 3% on a reported basis and 3% on a constant currency basis. Software revenue was $38.2 million in the second quarter, which increased 13% over the prior year period on a reported basis and on a constant currency basis. The growth in the quarter was driven by BioSimulation Software and Pinnacle 21. Radable and subscription revenue accounted for 65% of second quarter software revenues, up from 57% in the prior year period. Software bookings were $41.8 million in the second quarter, which increased 17% from the prior year period. Trailing 12-month software bookings were $145.5 million, up 11% -over-year. The software net retention rate was 108%, which is consistent with our long-term growth profile. Looking at our software bookings performance by tier, we saw very strong performance in both tier one and tier three customer segments, driven by continued adoption of our software. Now, turning to services revenue, which was $55.1 million in the second quarter, down 3% versus the prior year period, and on both a reported basis and a constant currency basis. Our services business continues to recover following a period of cautious spending among our customers. We were pleased to see improving performance in the tier three customer base, which we anticipate will continue, while tier one customers underperformed our internal expectations on cautious spending, as Bill mentioned earlier. Technology-driven services bookings in the second quarter were $57.1 million, which increased 14% from the prior year period. TTM services bookings were $262.9 million, down 2% as compared to the prior year. Total cost of revenue for the second quarter of 2024 was $39.8 million, an increase from $36.2 million in the second quarter of 2023, primarily due to a $2.8 million increase in employee-related expenses, a half a million dollar increase in stock-based compensation, and $0.8 million increase in software amortization. Total operating expenses for the second quarter of 2024 were $62.5 million, an increase from $41.2 million in the second quarter of 2023. Drivers of increased operating expenses included higher employee-related expenses due to recent acquisitions and planned investments in sales and marketing and research and development, along with higher stock-based compensation and transaction expenses related to the debt refinancing. Adjusted EBITDA for the second quarter of 2024 was $26.3 million, a decrease from $32.4 million in the second quarter of 2023. Adjusted EBITDA margin was 28.2%. We expect sequential improvement in adjusted EBITDA margin in the third quarter due to the realigned resources and cost reductions mentioned earlier, and so we remain confident in our full year adjusted EBITDA margin guidance of 31 to 33%. As Bill said in his remarks, after evaluating investments and cost allocation in the first half of the year, we have realigned resources to be more consistent with where we see the largest growth opportunities. Our focus remains on investing for growth, particularly in software and AI, while ensuring underperforming areas of the business are appropriately structured. Wrapping up the income statement, net loss for the second quarter of 2024 was $12.6 million compared to net income of $4.7 million in the second quarter of 2023. Reported adjusted net income for the second quarter of 2024 was $11.4 million compared to $18.4 million for the second quarter of 2023. Diluted loss per share for the second quarter of 2024 was 8 cents compared to earnings per share of 3 cents in the second quarter of 2023. Adjusted diluted earnings per share for the second quarter of 2024 was 7 cents compared to 12 cents for the second quarter of last year. Moving to the balance sheet, we finished the quarter with $224.6 million in cash and cash equivalents. As of June 30th, 2024, we had $296.7 million of outstanding borrowing on our term loan and full availability under our revolving credit facility. During the quarter, we took action to refinance our revolving credit facility and term loan in an effort to reduce our interest expense and push out maturities five to seven years respectively. These actions taken are expected to be accretive to fiscal 25 EPS by a penny and by two pennies from fiscal 26 through 31. We are reiterating our guidance for the full year 2024, excluding any impact from Kamaxon as follows. We expect total revenue in the range of $385 to $400 million representing growth of nine to 13% compared with 2023. Through the first half of 2024, we are tracking toward the lower half of the revenue range. We expect to grow adjusted EBITDA on a dollar figure basis in 2024 and expect an adjusted EBITDA margin in the range of 31 to 33%. Upon the closing of the Kamaxon transaction, we do expect to maintain our adjusted EBITDA margin guidance of 31 to 33%. We expect adjusted EPS in the range of 41 to 46 cents per share, fully diluted shares in the range of 160 to 162 million and a tax rate in the range of 25 to 30%. I will now turn the call back over to our CEO, William Furey, for closing remarks. Thank you,
spk05: John. To summarize our message today, we were pleased with the many exciting developments at Sertara in the second quarter and we remain focused on executing our growth and profitability goals in 2024. There's a lot to be excited about at Sertara as we advance bias simulation with our innovative technology. Operator, can you please open the line for questions?
spk08: Thank you. At this time, we will conduct the question
spk07: and answer session. As a reminder, to ask a question, you will need to press star 1-1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1-1 again. Please stand by for our first question.
spk08: Our first question comes from Jeff Garrow from Stevens.
spk07: Your line is now open.
spk02: Yeah, good afternoon. Thanks for taking the questions. Maybe start on the guidance and appreciate the direction there that you're tracking towards the lower half of the range on revenue. But maybe you could give some more comments on what gives you confidence that you won't slip below the bottom end of that range.
spk10: Yeah, hi Jeff. This is John. I can take that one. So, yeah, so as you pointed out, and we said in the remarks, we're tracking towards the lower half of the guidance range given the current environment. That's primarily due to the performance that we've seen in Q2 on the tier one services customers. So they are tracking below what our expectations were. But that being said, we do expect software to continue to do well. As we mentioned, we're seeing good signs in tier three customers, both in software and in services. And then if you take those together with typical seasonality that we've seen, including last year. So last year was a tough end market environment. We saw typical seasonality in Q4. Then that's what gives us the confidence on maintaining that range.
spk02: Excellent, that helps. Now maybe hit the profitability side a little bit. Was hoping you could speak a little bit more to the cost reductions. Maybe help us by calling out which line items will see more of an impact and then how we should think about the run rate of those actions on an annualized basis versus the impact we'll see in Q3. And then more strategically, why any cost reductions taken in recent weeks or months won't impact the long-term growth opportunity for the company, thanks.
spk06: Yeah, right.
spk10: So as we said, we were reallocating resources based on where we're seeing the biggest growth opportunities. So we're focusing the investment dollars on software and integrating AI. And then we were taking some cost actions as it related to areas that were underutilized or underperforming parts of the business. As far as how you see that showing up. So that's what gives us confidence in the guide on the EBITDA margin because those actions have already been taken and are showing up in the P&L now. So those will continue to flow through not only in Q3 but also in Q4. And the way to think about it is you should think about it as about a 500 basis point benefit or impact on percent revenue costs. And you'd see about 300 of that come on the cost of sales line and about
spk06: 200 coming off that. Maybe Will can
spk02: take the last part around why the cost actions won't impact the growth opportunity from here.
spk04: Oh yeah, thanks, Joe, appreciate it.
spk05: So I think we've just adjusted based on what we've seen as the current situation in the market. We haven't cut our investments in new products or in the long-term vision and health of Sitara. We've maintained our investments as John said in AI. Just we trimmed a little bit here and there based on what we saw in the market in just market demand in the short run that I think we're prudent to do. Some of it was just we just decided not to hire positions that we intended to hire. And we're committed to getting to our EBITDA margin guidance and it's one of the actions we took to get there.
spk02: Great, thanks for taking the questions.
spk08: Thank you. Our next question comes from David Wimbley from
spk07: Jeffries. Your line is now open.
spk01: Hi, thanks, good afternoon. Thanks for taking my questions. I wanted to pick up on where Jeff left off. I guess on the magnitude 500 basis points is pretty substantial. And I guess if I zoomed out, you entered this year with your bookings trajectory having been a little bit challenging and making the decision to actually spend a little bit more and invest in some growth I think targeted at R&D and sales and marketing. I see in your deck on your 2024 business update slide, you do talk about reduced spending in sales and marketing. And so I guess I wanted to understand a little bit the bigger picture about, Bill, appreciate your comments on current environment, but maybe what's changed in the six months since the decision to kind of double down on some investments as you entered 2024?
spk04: Yeah, thanks, David.
spk05: I'll start and then John can chime in with some of the numbers here. But I think what we saw as we went into 2024 is there's a tremendous opportunity for us to continue to invest in software and particularly in the AI investments that we started to make when we bought Viasa and into last year. We've continued to do them and they're starting to pay off. We've launched a product recently, which is just getting out there, but it's been very well received by customers. So we see those investments as worth continuing and paying off. What we saw during the first half of the year was we've had some, I think in the beginning part of the year, we had some softness in tier three, they've picked up as we went through the year. There's still a little bit of softness in tier ones as we go through. So that's particularly in the services side. And so it's relatively easier for us to adjust our cost position and services relative to the longer term investments in software. And so we took some necessary actions there. So John, if you wanna chime in on that?
spk10: Yeah, yeah, yeah, Bill. So hi, David. I think what we did there is we were slowing some headcount growth. So that's the piece of it. And we were really targeting, as Bill was just saying, we're targeting the underutilized areas of the business to take some costs out where it wasn't efficient. And so at the time that we did the guide on the fourth quarter call, we said that we had put together investments and we had expected the plan to play out in a certain way. And some of the plan isn't playing out in the way that we expected at the time that we did that guide. And we said, if that was the case, we would need to take actions to maintain the EBITDA. And we've done that. And we've done that as you would expect us to, basically because of what we saw happening with tier one services customers.
spk01: Okay, and if I could follow up on that, good segue there. In thinking about services, my intuition is that services with your big customers would maybe lean a little bit more toward regulatory and market access and smaller customers would lean a little bit more toward Biosim services. Is that right? Such that like the services weakness that you're seeing in tier one is in a different area than the weakness you maybe had seen in small and that's improving now in small or is it really in the same area, all in kind of Biosim?
spk10: It's really, it's in both. So it's, you know, the services weakness that we're seeing is both in regulatory and it's in Biosim services.
spk01: Okay, great, thanks. I'll follow up offline, thank you.
spk08: Thank you. Our next question comes from Michael Cherney
spk07: from Learing Partners. Your line is now open.
spk13: Great, thank you. This is Dan Clark on for Mike. First from us, how are you guys thinking about pricing on the services side just with these elongated, customer conversations on the tier one side? Like how do you kind of balance the discipline in pricing or price increases in getting deals done?
spk10: Yeah, I'd say that the price increases are more modest given the environment that we're in right now. The cost you spend and the slower decision making. We are still increasing price but we're increasing more modestly.
spk13: Thanks, and then just a quick modeling question. The customer summit you guys held in in 2Q, how should we think about the expense and the sales and marketing on just to kind of model the rest of the year there? Thank
spk10: you. Yeah, so as we were just saying, you know, the first half and the 2Q sales and marketing expenses is increasing based on the investment that we made and to some degree because of the M&A transactions that we brought in.
spk06: We
spk10: have taken actions as we were just discussing that are gonna slow head count growth and would slow the head count growth that we have on that line item
spk06: also. So thank you.
spk08: Thank you.
spk07: Our next question comes from Michael Riskin from B of A. Your line is now open.
spk09: Hi, this is Wolf from Mike. Thanks for taking the question, guys. I kind of want to pick back up on the guidance theme but perhaps just take a step back to end markets overall. I think we all kind of saw us mid biotech funding take a sequential step down in 2Q and thought that CRO or larger pharma spend with CROs and the like seemed fairly stable. Obviously you're kind of pointing to an opposite dynamic from that. So I'm just wondering if you can talk to how the tenor conversations with those two customers evolved over the course of the quarter.
spk04: Yeah, thanks for your question.
spk05: I think what we saw was there was a pickup in the small biotech funding in the first quarter. And then I think we believe that we saw that start to flow through in the second quarter. So there's some lag between what happens in funding and obviously when it reaches us. But the pickup was welcome because we had seen weakness in that segment for really quite some quarters now. So it was good to see them come back. I think on the larger customers, it's a, we saw just more caution around spending. It's certainly true in past years, we've seen pickups in the second half and particularly as you go into the very end of the year as customers want to spend their budget. So we're sort of cautiously watching what happens to that market. And obviously we factored that into the guidance
spk09: that we gave. Thank you. And then just one more kind of strategic one. Could you talk to the rationale behind the ChemAxon deal? Just interested in your kind of intent in expanding more into the preclinical space and what opportunities that you see there.
spk04: Yeah,
spk05: thanks
spk04: for the
spk05: question. So ChemAxon is an important acquisition for us. I think a lot of people have asked me for a while, what are some areas that we're interested in expanding in? And we've always talked about preclinical and the discovery space as being areas that are right for biosimulation to make a bigger impact. Most of the biosimulation help that we provide our clients in Sertara has been sort of preclinical and then especially in the clinical phase and we do really well there. But it's important to be able to help our clients make informed decisions on which drugs to take forward and which leads to optimize. We see an opportunity there to make a bigger impact on the overall success of drug development. And ChemAxon has quite a number of tools that we believe that we can integrate into a wider suite of biosimulation tools going forward to enable that. Wonderful, thank you for the answers guys.
spk08: Thank you. Our next question comes from Luke Sergot from
spk07: Barclays. Your line is now open.
spk11: This is Salem on for Luke. Thanks for the questions. Picking back off of Wolf's question on biotech and biotech funding, what's the expectation for the rest of the year? I know you're suspecting that you're seeing sort of the one queue pickup flowing through this quarter. But what's kind of embedded in the guide for the rest of the year on how those biotechs are gonna perform?
spk04: Yeah, thanks for the question John. You wanna take that one?
spk10: Yeah, yeah I got it Phil. The way to think through the customer tiering on the biotech for the remainder of the year is we are not planning an uplift on tier three. We were pleased to see a bit of an uptick in Q2, but we have the guide really contemplate a continuation of just sort of stability on the tier three customer base. But that being said, I mentioned earlier we do anticipate typical seasonality. So turning to tier one customers, the guide does contemplate a pickup in tier one customer activity in Q4, which is what we've seen historically and importantly we saw last year during a time also that had a difficult end market environment. So that's the only piece of seasonality or uptick that we really have planned into the guidance.
spk11: Gotcha, that's really helpful. And then a follow up on just software bookings. You mentioned maybe some strength is driven by expansion of bio simulation to new customers. Is this mostly driven by new offerings? And I'm kinda curious if co-author was a significant portion of bookings due to the new unveil. Or is this more of a side effect of the commercial reorg? And could you just give us an update on the progress there and how it's trending versus your expectations on synergies? Thanks.
spk05: Yeah, thanks. Maybe I'll start with that one, John. So we saw a nice growth in our core software products and particularly SimSip and Pinnacle 21. So that was good to see. Co-author was just sort of fully launched at the end of June. So it's a bit too early for that to be a significant impact on our bookings, but we did have a pretty big launch and we've received quite a bit of interest for that product. So let's watch as we go forward, but it didn't play a significant effect to the numbers that we reported for the quarter. And I'd say across the board, we saw a lot of interest in AI. There's been basically a steady stream of feature launches and product extensions in our SimSip family, which has contributed a lot to the growth. So those are the kind of, I would say it's kind of in the core software areas that we saw the best growth.
spk06: Awesome, appreciate it.
spk08: Thank you.
spk07: Our next question comes from Joe Ruhrink from Baird. Your line is now open.
spk12: Great, hi everyone. If the smaller customers are buying by simulation software and starting to become more visible in the services pipeline, is there any history for you to say that your large customers tend to follow the small customers within a matter of some quarters? Or is this the current regulatory environment the large customers are dealing with so different that it kind of muddies any historical comparisons you might make?
spk04: Yeah, thanks, Joe. It's a good question. I think we see them as the markets
spk05: operating a little bit differently. We think that, what we've seen was the large customers have gone through a period of, a number of them are rethinking their, large portfolios of drugs, which ones they're gonna continue to take forward and which ones they're not. Obviously that's not really the question for the smaller ones who are trying to, most of them are trying to get funded for one drug or one platform. So I'm not sure that we tend to see, what do you wanna call it, a causal link like you're talking about. Now obviously, biotechs often go through M&A with larger customers at some point. So maybe somewhere down the line that'll be in effect, but it's not really in our thinking for the rest of the year.
spk12: Okay, thank you. And then just the comfort backdrop specifically for regulatory services, any risks that that carries over to your regulatory focus software offerings or you mentioned at the start of the call just large customers very focused on cost reductions and efficiencies is a tougher environment you're seeing on the services side actually beneficial in bringing up things like Pinnacle or maybe it creates an even more favorable launch environment for something like CoAuthr.
spk05: Well, CoAuthr is a pretty interesting tool. We've, in our internal testing, we've seen pretty substantial reductions in the amount of hours it takes to create regulatory documents. And so I think in any type of environment that significant cost savings like that are a good pitch and so that's why we're getting, I think we're being well received there. I think it helps that we have a regulatory business and so we've used that experience to inform the creation of that product. So it's kind of think of that as, we had this product almost designed by the users of the software and so that's given us a pretty good sense on how to design something that's truly useful in that market. I would say we still see continued spending across the board by customers on software, most of whom look at the software as, once you're in there they tend to look at it as continued investment in their infrastructure. So as long as they're gonna continue to do R&D, they're gonna need most of our software and so the discussions around how much renewal and what are we doing with new features and new extensions and things like that. So I think that's one reason why we've seen that as a stronger market right now, whereas the services have tended to be more project-based as people adjust their portfolios and they stop some drugs and they start others, there's some disruption to the flow of projects that come through to us and so that's been a factor this year.
spk12: Okay, I'll leave it there, thank you very much.
spk07: Thank you. As a reminder, to ask a question, you will need to press star one one on your telephone and wait for your name to be announced.
spk08: Our next question comes from Max Reims
spk07: from William Blair. Your line is now open.
spk14: Hey, good afternoon, thanks for taking our questions. I wanted to ask a question along the same line as Wolf's question earlier. So on the services side, given we've seen clinical CROs hold out pretty well, is it fair to assume that at least a chunk of these programs and large pharma are moving forward but they're electing to do so maybe without a lot of work? I'm wondering if you're thinking about your consulting services or do you really think it's more a function of the fact that you're missing out on bidding and working on these clinical programs that are actually being paused and reevaluated and therefore maybe there's a potential for you all to still recognize revenue from these programs in the back half of the year or 2025 as they potentially move forward?
spk05: Yeah, we do believe that and in addition we point to the fact that we did see an uptick in services bookings in the second quarter. So I would say too early to call a huge recovery in the market but we are seeing improvement in the overall environment as we move forward to the second half of the year. I don't know, John, if you wanna comment on that.
spk10: Yeah, yeah, I think we anticipate having, when we did the guide we said it would be a first half, second half story. Particularly on services and we're seeing that in the way that this year is playing out we'd anticipate to have 49% first half, 51, 52% second half and so we typically do see services pick up in the latter part of the year and namely in Q4 and so that's the typical seasonality that we've been referring to and that we saw last year. So we do think that that'll be a component of how this year plays out also.
spk14: Got it, that's helpful, thank you. And then maybe sticking on the services bookings side. I guess it sounds like based on your comment there they were relatively in line with your expectations but any comment around what you're looking for in the quarter and then how services bookings in particular stacked up. I know when we talked last quarter you kinda pointed us to 2021 and 2022 from a seasonality perspective. Looks like the average set down in those years was about 10% sequentially and they were down about 20% sequentially here in the second quarter of this year. So any comment around just how services bookings kinda stacked up to your expectations here in the second quarter?
spk10: Yeah, so I mean the services bookings did come in later than we had expected given the tier one performance that we had seen. But that being said, services bookings did grow 14% year on year. And as we look forward to the second half then, as I mentioned I think probably the key component in the second half is the seasonality that we've seen and we saw last year importantly. So we're not anticipating anything outsized in that seasonality compared to what we saw last year.
spk06: Got it, thanks for taking our questions. Mm-hmm.
spk08: Thank you. Our next question comes from Steve Deckert from KeyBank.
spk07: Your line is now open.
spk02: Hey guys, just wondering if you think the launch of Cert Cloud had an
spk06: impact on your second quarter bookings, thanks. It's still early
spk10: days Steve for Certara Cloud to have a material impact on the bookings. So the answer to that, although as we said, our software bookings and our software revenue continues to be strong. We don't see any reason for that to change and Certara Cloud is the key component of our strategy going forward. And we think that that's gonna enable not just that product but all of the products in our portfolio. But for Q2 that wouldn't have been
spk06: a meaningful part of our bookings.
spk07: Thank
spk06: you.
spk07: Thank you. This concludes our question and answer session. Thank you for your participation in today's conference. This does conclude our program. You may now disconnect.
Disclaimer